BE2010C031I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2010C031I2 BE2010C031I2 BE2010C031C BE2010C031C BE2010C031I2 BE 2010C031 I2 BE2010C031 I2 BE 2010C031I2 BE 2010C031 C BE2010C031 C BE 2010C031C BE 2010C031 C BE2010C031 C BE 2010C031C BE 2010C031 I2 BE2010C031 I2 BE 2010C031I2
- Authority
- BE
- Belgium
- Prior art keywords
- conjugate
- meningococcal serogroup
- buffer
- aluminium
- provides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/04—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from fish or other sea animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
- A23J1/205—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey from whey, e.g. lactalbumine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09F—NATURAL RESINS; FRENCH POLISH; DRYING-OILS; DRIERS (SICCATIVES); TURPENTINE
- C09F1/00—Obtaining purification, or chemical modification of natural resins, e.g. oleo-resins
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09G—POLISHING COMPOSITIONS; SKI WAXES
- C09G1/00—Polishing compositions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0115176.0A GB0115176D0 (en) | 2001-06-20 | 2001-06-20 | Capular polysaccharide solubilisation and combination vaccines |
PCT/IB2002/003191 WO2003007985A2 (fr) | 2001-06-20 | 2002-06-20 | Solubilisation de polysaccharides capsulaires et vaccins de combinaison |
Publications (1)
Publication Number | Publication Date |
---|---|
BE2010C031I2 true BE2010C031I2 (fr) | 2021-07-19 |
Family
ID=9917070
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2010C031C BE2010C031I2 (fr) | 2001-06-20 | 2010-09-13 | |
BE2010C033C BE2010C033I2 (fr) | 2001-06-20 | 2010-09-13 | |
BE2010C032C BE2010C032I2 (fr) | 2001-06-20 | 2010-09-13 | |
BE2011C001C BE2011C001I2 (fr) | 2001-06-20 | 2011-01-13 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2010C033C BE2010C033I2 (fr) | 2001-06-20 | 2010-09-13 | |
BE2010C032C BE2010C032I2 (fr) | 2001-06-20 | 2010-09-13 | |
BE2011C001C BE2011C001I2 (fr) | 2001-06-20 | 2011-01-13 |
Country Status (23)
Country | Link |
---|---|
US (9) | US8753651B2 (fr) |
EP (10) | EP2277536B1 (fr) |
JP (4) | JP5075317B2 (fr) |
CN (4) | CN100482273C (fr) |
AT (3) | ATE556718T1 (fr) |
AU (3) | AU2002321716B2 (fr) |
BE (4) | BE2010C031I2 (fr) |
BR (2) | BR122019009186B8 (fr) |
CA (3) | CA2730856C (fr) |
CY (6) | CY1110820T1 (fr) |
DE (6) | DE122010000042I1 (fr) |
DK (6) | DK1741442T3 (fr) |
ES (9) | ES2603275T3 (fr) |
FR (4) | FR10C0043I1 (fr) |
GB (1) | GB0115176D0 (fr) |
LU (4) | LU91732I2 (fr) |
MX (1) | MXPA03011462A (fr) |
NL (3) | NL300459I2 (fr) |
NZ (2) | NZ529881A (fr) |
PT (6) | PT1401489E (fr) |
RU (2) | RU2381814C2 (fr) |
TR (2) | TR201808055T4 (fr) |
WO (1) | WO2003007985A2 (fr) |
Families Citing this family (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9928196D0 (en) | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
AP1897A (en) | 2001-01-23 | 2008-10-10 | Aventis Pasteur | Multivalent Meningococcal polysaccharide-Protein Conjugate Vaccine. |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
GB0118249D0 (en) * | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
PT1490409E (pt) * | 2002-03-26 | 2009-04-03 | Novartis Vaccines & Diagnostic | Sacáridos modificados possuindo uma estabilidade melhorada em água |
GB0302218D0 (en) | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
MXPA04011249A (es) | 2002-05-14 | 2005-06-06 | Chiron Srl | Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos. |
EP1961427A3 (fr) * | 2002-08-02 | 2009-11-04 | GlaxoSmithKline Biologicals S.A. | Vaccin antineisseria comprenant une combinaison d'antigenes |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
SI2351579T1 (sl) * | 2002-10-11 | 2017-05-31 | Glaxosmithkline Biologicals Sa | Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam |
WO2004046177A2 (fr) | 2002-11-15 | 2004-06-03 | Chiron Srl | Proteines de surface inattendues sur le meningocoque |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
US10272147B2 (en) * | 2003-01-30 | 2019-04-30 | Glaxosmithkline Biologicals S.A. | Injectable vaccines against multiple meningococcal serogroups |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
JP4918356B2 (ja) * | 2003-06-23 | 2012-04-18 | バクスター・インターナショナル・インコーポレイテッド | Y群髄膜炎菌ワクチン及びそれらの髄膜炎菌組合せワクチン |
CN103405761A (zh) * | 2003-10-02 | 2013-11-27 | 诺华疫苗和诊断有限公司 | 多种脑膜炎球菌血清群的液体疫苗 |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
GB0406013D0 (en) * | 2004-03-17 | 2004-04-21 | Chiron Srl | Analysis of saccharide vaccines without interference |
GB0408978D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Meningococcal fermentation for preparing conjugate vaccines |
GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
NZ550533A (en) | 2004-04-30 | 2010-02-26 | Novartis Vaccines & Diagnostic | Meningococcal conjugate vaccination comprising N. meningitidis and diphtheria toxin |
GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
GB0411387D0 (en) | 2004-05-21 | 2004-06-23 | Chiron Srl | Analysis of saccharide length |
GB0413868D0 (en) * | 2004-06-21 | 2004-07-21 | Chiron Srl | Dimensional anlaysis of saccharide conjugates |
EP1784214A4 (fr) * | 2004-08-30 | 2009-09-23 | Sanofi Pasteur Inc | Conjugués polysaccharide/protéine dérivatisés de méningocoque multivalents et vaccin |
JP2008513541A (ja) * | 2004-09-21 | 2008-05-01 | サノフィ パストゥール インコーポレイテッド | 多価髄膜炎菌誘導体化多糖−タンパク質複合体およびワクチン |
GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
GB0502096D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Purification of streptococcal capsular polysaccharide |
SG160329A1 (en) | 2005-02-18 | 2010-04-29 | Novartis Vaccines & Diagnostic | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
ES2385045T3 (es) | 2005-02-18 | 2012-07-17 | Novartis Vaccines And Diagnostics, Inc. | Inmunógenos de Escherichia coli uropatogénica |
GB0505518D0 (en) * | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
EP2425852A1 (fr) | 2005-04-08 | 2012-03-07 | Wyeth LLC | Composition conjuguée polysaccharide-protéine pneumococcique polyvalente |
JP2008536515A (ja) | 2005-04-18 | 2008-09-11 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | ワクチンの調製のためのb型肝炎ウイルス表面抗原の発現 |
GB0513069D0 (en) * | 2005-06-27 | 2005-08-03 | Glaxosmithkline Biolog Sa | Immunogenic composition |
EP3009146B1 (fr) * | 2005-06-27 | 2021-10-20 | Pfizer Ireland Pharmaceuticals | Composition immunogène |
GB0513071D0 (en) * | 2005-06-27 | 2005-08-03 | Glaxosmithkline Biolog Sa | Immunogenic composition |
EP2308504A3 (fr) | 2005-09-01 | 2011-11-30 | Novartis Vaccines and Diagnostics GmbH | Vaccins multiples comprenant le sérogroupe C de Neisseria meningitidis |
JP5047969B2 (ja) * | 2005-09-05 | 2012-10-10 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 髄膜炎菌特異的抗血清に対する血清殺菌アッセイ |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
KR101411425B1 (ko) | 2006-03-17 | 2014-06-24 | 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 | 복합 다가 면역원성 콘쥬게이트의 제조 방법 |
ES2383209T3 (es) | 2006-03-22 | 2012-06-19 | Novartis Ag | Regímenes para la inmunización con conjugados meningococicos |
US10828361B2 (en) * | 2006-03-22 | 2020-11-10 | Glaxosmithkline Biologicals Sa | Regimens for immunisation with meningococcal conjugates |
GB0605757D0 (en) | 2006-03-22 | 2006-05-03 | Chiron Srl | Separation of conjugated and unconjugated components |
TW200806315A (en) * | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
CN101081296B (zh) * | 2006-05-29 | 2010-08-04 | 北京民海生物科技有限公司 | 一种b型流感嗜血杆菌荚膜多糖制备方法及其联合疫苗 |
US7491517B2 (en) | 2006-07-19 | 2009-02-17 | Jeeri R Reddy | Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135 |
JP2010500399A (ja) | 2006-08-16 | 2010-01-07 | ノバルティス アーゲー | 尿路病原性大腸菌由来の免疫原 |
JP5260531B2 (ja) * | 2006-10-10 | 2013-08-14 | ワイス・エルエルシー | 肺炎連鎖球菌3型多糖体の精製 |
GB0700136D0 (en) | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Process for manufacturing vaccines |
GB0700562D0 (en) * | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
CL2008000831A1 (es) * | 2007-03-23 | 2008-07-04 | Wyeth Corp | Procesos para extraer exceso de proteina soluble e impurezas a partir de lisados celulares de serotipos de streptococcus pneumoniae utilizados en la produccion de polisacaridos neumococales. |
WO2008129559A2 (fr) * | 2007-04-23 | 2008-10-30 | Serum Institute Of India Ltd | Polysaccharides antigéniques et procédé pour leur préparation |
BRPI0811979A2 (pt) * | 2007-06-04 | 2014-10-21 | Novartis Ag | Formulação para vacinas de meningite |
GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
CA2698157C (fr) * | 2007-09-11 | 2016-10-11 | University Of Guelph | Nouveaux polysaccharides immunogenes issus de clostridium difficile |
CN101951949B (zh) | 2007-10-19 | 2013-10-02 | 诺华股份有限公司 | 脑膜炎球菌疫苗制剂 |
AU2009215364B2 (en) | 2008-02-21 | 2014-09-18 | Glaxosmithkline Biologicals S.A. | Meningococcal fHBP polypeptides |
CN101724085B (zh) * | 2008-10-22 | 2011-09-21 | 上海生物制品研究所 | 一种荚膜多糖纯化方法 |
HUE029265T2 (en) | 2008-10-27 | 2017-02-28 | Glaxosmithkline Biologicals Sa | Method of purifying carbohydrates from the group streptococci |
GB0822633D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
JP2012512240A (ja) | 2008-12-17 | 2012-05-31 | ノバルティス アーゲー | ヘモグロビン受容体を含む髄膜炎菌ワクチン |
BR112012004275A2 (pt) | 2009-08-27 | 2016-11-16 | Novartis Ag | polipeptídios híbridos incluindo sequências meningocócicas de fhbp |
ES2812523T3 (es) | 2009-09-30 | 2021-03-17 | Glaxosmithkline Biologicals Sa | Conjugación de polisacáridos capsulares de Staphylococcus aureus de tipo 5 y de tipo 8 |
MX2012004850A (es) | 2009-10-27 | 2012-05-22 | Novartis Ag | Polipeptidos fhbp meningococicos modificados. |
CN102971009A (zh) | 2009-10-30 | 2013-03-13 | 诺华有限公司 | 金黄色葡萄球菌5型和8型荚膜多糖的纯化 |
CN102802662A (zh) | 2010-03-18 | 2012-11-28 | 诺华有限公司 | 用于脑膜炎球菌血清组b的含佐剂疫苗 |
ES2639035T3 (es) | 2010-08-23 | 2017-10-25 | Wyeth Llc | Formulaciones estables de antígenos rLP2086 de Neisseria meningitidis |
WO2012031271A1 (fr) | 2010-09-04 | 2012-03-08 | Novartis Ag | Dosages d'anticorps bactéricides pour évaluer l'immunogénicité et la puissance de vaccins contre le méningocoque constitués de saccharides capsulaires |
RU2546873C2 (ru) | 2010-09-10 | 2015-04-10 | УАЙТ ЭлЭлСи | Нелипидизированные варианты антигенов neisseria meningitidis orf2086 |
GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
CA2860331A1 (fr) | 2010-12-24 | 2012-06-28 | Novartis Ag | Composes |
KR20140026392A (ko) | 2011-03-02 | 2014-03-05 | 노파르티스 아게 | 저용량의 항원 및/또는 보조제를 갖는 조합 백신 |
US9149541B2 (en) | 2011-07-08 | 2015-10-06 | Novartis Ag | Tyrosine ligation process |
CU20110202A7 (es) | 2011-11-02 | 2013-12-27 | Inst Finlay Ct De Investigación Producción De Sueros Y Vacunas | Composición inmunogénica de polisacáridos planos adyuvados y las formulaciones resultantes |
CN104080479B (zh) * | 2011-11-07 | 2019-11-05 | 葛兰素史密丝克莱恩生物有限公司 | 包括spr0096和spr2021抗原的运载体分子 |
PT2809349T (pt) * | 2012-01-30 | 2019-02-01 | Serum Institute Of India Pvt Ltd | Composição imunogénica |
EP2822584A1 (fr) | 2012-03-08 | 2015-01-14 | Novartis AG | Vaccins combinés comprenant des agonistes du tlr4 |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
AU2013229063B2 (en) | 2012-03-09 | 2016-10-06 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
CN104736180A (zh) | 2012-05-22 | 2015-06-24 | 诺华股份有限公司 | 脑膜炎球菌血清组x偶联物 |
CN104487086B (zh) * | 2012-07-07 | 2019-08-30 | 巴拉特生物技术国际有限公司 | 无动物源的不含酒精的疫苗组合物及其制备方法 |
CN103623404B (zh) * | 2012-08-28 | 2016-08-03 | 天士力制药集团股份有限公司 | 一种b型流感嗜血杆菌多糖结合疫苗的制备方法 |
AU2013311702A1 (en) | 2012-09-06 | 2015-02-19 | Novartis Ag | Combination vaccines with serogroup B meningococcus and D/T/P |
SG11201503947YA (en) * | 2012-11-21 | 2015-06-29 | Serum Inst India Ltd | Production of high yields of bacterial polysaccharides |
CN105007935A (zh) | 2012-12-18 | 2015-10-28 | 葛兰素史密丝克莱恩生物有限公司 | 用于保护免于白喉和/或破伤风的缀合物 |
EP2964665B1 (fr) | 2013-03-08 | 2018-08-01 | Pfizer Inc | Polypeptides immunogènes de fusion |
AU2014286990A1 (en) | 2013-07-11 | 2016-02-11 | Novartis Ag | Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase |
WO2015005961A1 (fr) | 2013-07-12 | 2015-01-15 | Emd Millipore Corporation | Méthode permettant de déterminer si un virus peut être éliminé d'un échantillon contenant une protéine cible à l'aide de charbon actif |
KR20210002757A (ko) | 2013-09-08 | 2021-01-08 | 화이자 인코포레이티드 | 나이세리아 메닌지티디스 조성물 및 그의 방법 |
SG11201606478YA (en) | 2014-02-28 | 2016-09-29 | Glaxosmithkline Biolog Sa | Modified meningococcal fhbp polypeptides |
WO2015181834A2 (fr) | 2014-05-24 | 2015-12-03 | Biological E Limited | Nouveau vaccin conjugué méningococcique semi-synthétique |
CN104548090B (zh) * | 2015-01-27 | 2016-11-30 | 中国科学院过程工程研究所 | 一种β-葡聚糖修饰的脑膜炎多糖结合疫苗及其制备方法 |
RU2723045C2 (ru) | 2015-02-19 | 2020-06-08 | Пфайзер Инк. | Композиции neisseria meningitidis и способы их получения |
CN105037579A (zh) * | 2015-08-31 | 2015-11-11 | 成都欧林生物科技股份有限公司 | A群脑膜炎球菌细菌荚膜粗多糖的制备工艺 |
WO2017175082A1 (fr) | 2016-04-05 | 2017-10-12 | Gsk Vaccines S.R.L. | Compositions immunogènes |
CA3035320A1 (fr) | 2016-09-02 | 2018-03-08 | Glaxosmithkline Biologicals Sa | Vaccins contre neisseria gonorrhoeae |
KR20190044663A (ko) | 2016-09-02 | 2019-04-30 | 사노피 파스퇴르 인크 | 네이세리아 메닌기티디스 백신 |
US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
IL303108B1 (en) | 2017-01-31 | 2024-03-01 | Pfizer | NEISSERIA MENINGITIDIS preparations and methods therefor |
CA3052621A1 (fr) | 2017-02-03 | 2018-08-09 | Schadeck, Eva Barbara | Compositions de conjugue saccharide d'haemophilus influenzae-excipient et leurs utilisations |
US11400162B2 (en) | 2017-02-24 | 2022-08-02 | Merck Sharp & Dohme Llc | Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein |
WO2018156467A1 (fr) * | 2017-02-24 | 2018-08-30 | Merck Sharp & Dohme Corp. | Procédés d'amélioration de la filtrabilité de réactions de polysaccharide conjugué à une protéine |
KR102565771B1 (ko) * | 2017-05-05 | 2023-08-10 | 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 | 박테리아 협막 폴리사카라이드 기반 제제로부터의 불순물의 제거 방법 |
CN110892077A (zh) * | 2017-05-17 | 2020-03-17 | 默沙东和惠康基金会合资的希勒曼实验室私人有限公司 | 细菌多糖的纯化 |
KR20200051698A (ko) * | 2017-09-07 | 2020-05-13 | 머크 샤프 앤드 돔 코포레이션 | 담체 단백질에의 접합을 위한 폐렴구균 폴리사카라이드의 제제화 방법 |
WO2019175900A1 (fr) * | 2018-03-16 | 2019-09-19 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Purification de polysaccharides de neisseria meningitidis |
US20220211859A1 (en) | 2019-05-10 | 2022-07-07 | Glaxosmithkline Biologicals Sa | Conjugate production |
BR112022008761A2 (pt) | 2019-11-22 | 2022-07-26 | Glaxosmithkline Biologicals Sa | Dosagem e administração de uma vacina de glicoconjugado de sacarídeo |
GB202013262D0 (en) | 2020-08-25 | 2020-10-07 | Glaxosmithkline Biologicals Sa | Vaccine Composition |
CN115721709A (zh) * | 2021-08-27 | 2023-03-03 | 康希诺生物股份公司 | 一种肺炎球菌结合疫苗制备方法 |
GB202115151D0 (en) | 2021-10-21 | 2021-12-08 | Glaxosmithkline Biologicals Sa | Methods |
GB202208089D0 (en) * | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
GB202208093D0 (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
Family Cites Families (146)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB207117A (en) | 1923-04-05 | 1923-11-22 | Fernand Prosper Constant Lebru | Improvements in otter boards |
US4057685A (en) | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
US4123520A (en) * | 1977-08-01 | 1978-10-31 | Merck & Co., Inc. | Method for preparing high molecular weight meningococcal Group C vaccine |
US4134214A (en) | 1977-08-05 | 1979-01-16 | Merck & Co., Inc. | Freeze-drying process for the preparation of meningococcus vaccine without degradation of potency |
DE2748132A1 (de) | 1977-10-27 | 1979-05-03 | Behringwerke Ag | Stabilisator fuer polysaccharid |
US4220717A (en) * | 1977-12-22 | 1980-09-02 | American Cyanamid Company | Isolation and purification of polyribosyl ribitol phosphate from Haemophilus influenzae type b. |
US4242501A (en) * | 1979-08-08 | 1980-12-30 | American Cyanamid Company | Purification of pneumococcal capsular polysaccharides |
US4351762A (en) * | 1981-03-10 | 1982-09-28 | Bioresearch, Inc. | Rapid, quantitative peptide synthesis using mixed anhydrides |
US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
BE889979A (fr) * | 1981-08-14 | 1982-02-15 | Smith Kline Rit | Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4902506A (en) | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
US4451446A (en) * | 1982-03-04 | 1984-05-29 | Smithkline-Rit | Process for the preparation of polysaccharide-protein complexes from bacterial capsules, obtained products and immunogenic compositions containing them |
US4496538A (en) * | 1982-07-06 | 1985-01-29 | Connaught Laboratories, Inc. | Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine |
JPS59176214A (ja) * | 1982-11-23 | 1984-10-05 | ザ・ウエルカム・フアウンデ−シヨン・リミテツド | 抗原性組成物 |
EP0109688A3 (fr) * | 1982-11-23 | 1986-12-03 | The Wellcome Foundation Limited | Complexes, procédés pour leur obtention et formulations contenant de tels complexes |
US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
US4663160A (en) | 1983-03-14 | 1987-05-05 | Miles Laboratories, Inc. | Vaccines for gram-negative bacteria |
US4761283A (en) * | 1983-07-05 | 1988-08-02 | The University Of Rochester | Immunogenic conjugates |
US4762713A (en) * | 1983-07-05 | 1988-08-09 | The University Of Rochester | Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers |
EP0145359B1 (fr) * | 1983-11-21 | 1991-01-16 | The Wellcome Foundation Limited | Complexes, leur procédé de préparation et formulations les contenant |
US4882317A (en) | 1984-05-10 | 1989-11-21 | Merck & Co., Inc. | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency |
US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
US4808700A (en) | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
US4814276A (en) * | 1986-04-25 | 1989-03-21 | Becton, Dickinson And Company | Selective medium for growth of neisseria |
US4877613A (en) | 1987-08-05 | 1989-10-31 | Biotech Connections, Inc. | Process for preparing veterinary acellular vaccines against gram-negative nonenteric pathogenic bacilli |
US4761713A (en) * | 1987-11-06 | 1988-08-02 | North American Philips Corp. | Glycol based mid-volt capacitor |
GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
NL8802046A (nl) | 1988-08-18 | 1990-03-16 | Gen Electric | Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen. |
DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
AU640118B2 (en) | 1988-12-19 | 1993-08-19 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur | Meningococcal class 1 outer-membrane protein vaccine |
CA2006700A1 (fr) | 1989-01-17 | 1990-07-17 | Antonello Pessi | Peptides synthetiques et leur utilisation comme porteurs universels pour la preparation de conjugats immunogenes convenant a la mise au point de vaccins synthetiques |
US4963534A (en) | 1989-05-19 | 1990-10-16 | Merck & Co., Inc. | Process for solubilizing polyanoinic bacterial polysaccharides in aprotic solvents |
CA2017507C (fr) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant constitue d'une emulsion de gouttelettes submicron d'huile |
KR920703114A (ko) | 1989-07-14 | 1992-12-17 | 원본미기재 | 접합체 백신을 위한 시토킨 및 호르몬 운반체 |
IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
DE69019164T2 (de) * | 1989-12-14 | 1995-09-07 | Ca Nat Research Council | Verbessertes meningokokkale polysaccharidkonjugatvakzin. |
EP0471177B1 (fr) | 1990-08-13 | 1995-10-04 | American Cyanamid Company | Hemagglutinine filamenteuse de Bordetella pertussis à titre de molécules porteuses pour vaccins conjugués |
US5256294A (en) * | 1990-09-17 | 1993-10-26 | Genentech, Inc. | Tangential flow filtration process and apparatus |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
CA2059693C (fr) * | 1991-01-28 | 2003-08-19 | Peter J. Kniskern | Antigenes polysaccharides de streptococcus pneumoniae |
CA2059692C (fr) * | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Vaccin conjugue de polysaccharide contre les pneumocoques |
JP2631035B2 (ja) * | 1991-03-12 | 1997-07-16 | アメリカ合衆国 | 多糖類−タンパク質複合体 |
US5314811A (en) * | 1992-07-13 | 1994-05-24 | Merck & Co., Inc. | Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide |
WO1993004183A1 (fr) * | 1991-08-16 | 1993-03-04 | Merck & Co., Inc. | Procede de conversion d'un polysaccharide capsulaire bacterien contenant des lipides en polysaccharide sans lipide |
FR2682388B1 (fr) * | 1991-10-10 | 1995-06-09 | Pasteur Merieux Serums Vacc | Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal. |
DE69334197T2 (de) | 1992-03-02 | 2008-12-11 | Novartis Vaccines And Diagnostics S.R.L. | Helicobacter pylori Cytotoxin verwendbar in Impfstoffe und Diagnostik |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
DE122010000015I1 (de) | 1992-05-23 | 2010-07-08 | Glaxosmithkline Biolog Sa | Kombinierte Impfstoffe, die Hepatitis-B-Oberflächen antigen und andere Antigene enthalten |
ES2143716T3 (es) | 1992-06-25 | 2000-05-16 | Smithkline Beecham Biolog | Composicion de vacuna que contiene adyuvantes. |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
EP0689454B2 (fr) | 1993-03-23 | 2005-02-23 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Compositions vaccinales renfermant le lipide a monophosphorylique 3-o desacetyle |
JP3828145B2 (ja) * | 1993-09-22 | 2006-10-04 | ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン | 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法 |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
EP0769018B1 (fr) | 1994-07-01 | 2002-12-18 | Chiron Corporation | Proteines d'helicobacter et vaccins |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
DE69535905D1 (de) | 1994-07-15 | 2009-02-26 | Coley Pharm Group Inc | Immunomodulatorische Oligonukleotide |
GB9422096D0 (en) * | 1994-11-02 | 1994-12-21 | Biocine Spa | Combined meningitis vaccine |
US6696065B1 (en) * | 1995-05-04 | 2004-02-24 | Aventis Pastuer Limited | Acellular pertussis vaccines and methods of preparation thereof |
US5811102A (en) * | 1995-06-07 | 1998-09-22 | National Research Council Of Canada | Modified meningococcal polysaccharide conjugate vaccines |
JP4233113B2 (ja) | 1995-06-07 | 2009-03-04 | グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム | 多糖類抗原−キャリア蛋白接合体および遊離キャリア蛋白を有してなるワクチン |
US20030157129A1 (en) * | 1995-06-23 | 2003-08-21 | Smithkline Beecham Biologicals S.A. | Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein |
US20020054884A1 (en) * | 1995-06-23 | 2002-05-09 | Smithkline Beecham Biologicals, Sa | Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate |
EP1082965B1 (fr) * | 1995-06-23 | 2009-06-10 | GlaxoSmithKline Biologicals S.A. | Vaccin comprenant comme antigène un polysaccharide conjugé, adsorbé sur du phosphate d'aluminium |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
PT909323E (pt) | 1996-01-04 | 2007-06-04 | Novartis Vaccines & Diagnostic | ''bacterioferritina de helicobacter pilori'' |
IL125420A0 (en) | 1996-02-01 | 1999-03-12 | North American Vaccine Inc | Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines containing said protein |
ATE280834T1 (de) * | 1996-02-14 | 2004-11-15 | Merck & Co Inc | Verfahren zur präzipitation von polysacchariden |
DE19630390A1 (de) | 1996-07-26 | 1998-01-29 | Chiron Behring Gmbh & Co | Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung |
WO1998008543A1 (fr) | 1996-08-27 | 1998-03-05 | Chiron Corporation | Glycoconjugues du groupe serologique b de neisseria meningitidis et leurs procedes d'utilisation |
ATE292980T1 (de) | 1996-10-11 | 2005-04-15 | Univ California | Immunostimulierende oligonucleotidekonjugate |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
US6248334B1 (en) | 1997-01-08 | 2001-06-19 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process |
DE69841362D1 (de) * | 1997-01-21 | 2010-01-21 | Sanofi Pasteur | Polysaccharid-peptid-konjugate |
ES2229477T3 (es) | 1997-01-24 | 2005-04-16 | Berna Biotech Ag | Procedimiento nuevo para el aislamiento de polisacaridos. |
EP1039935A4 (fr) | 1997-02-28 | 2005-04-27 | Univ Iowa Res Found | UTILISATION D'ACIDES NUCLEIQUES CONTENANT DES DINUCLEOTIDES CpG NON METHYLES DANS LE TRAITEMENT DES TROUBLES ASSOCIES AUX LIPOPOLYSACCHARIDES |
WO1998040100A1 (fr) | 1997-03-10 | 1998-09-17 | Ottawa Civic Loeb Research Institute | UTILISATION D'ACIDES NUCLEIQUES CONTENANT UN DINUCLEOTIDE CpG NON METHYLE EN TANT QU'ADJUVANT |
US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
US6403306B1 (en) | 1997-04-09 | 2002-06-11 | Emory University | Serogroup-specific nucleotide sequences in the molecular typing of bacterial isolates and the preparation of vaccines thereto |
EP0977588B1 (fr) | 1997-04-24 | 2004-10-06 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Couplage de proteines non modifiees a des polysaccharides derives d'haloacyle ou de dihaloacyle pour la preparation de vaccins renfermant des proteines-polysaccharides |
AU7690898A (en) | 1997-05-20 | 1998-12-11 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
WO1998054296A1 (fr) | 1997-05-28 | 1998-12-03 | Chiron S.P.A. | Milieu de culture renfermant de la levure ou de l'extrait de soja comme sources d'acides amines mais exempt de complexes proteiniques d'origine animale |
ES2326848T3 (es) | 1997-06-06 | 2009-10-20 | The Regents Of The University Of California | Inhibidores de la actividad de secuencias inmunoestimulatorias de adn. |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
WO1998058670A1 (fr) | 1997-06-24 | 1998-12-30 | Chiron Corporation | Procedes permettant d'immuniser des adultes grace a des compositions de vaccins anti-meningococcique |
DE69842224D1 (de) * | 1997-08-27 | 2011-05-26 | Childrens Hosp Medical Center | Molekular-mimetika von meningokokkalen B Epitopen |
ES2201551T3 (es) | 1997-09-05 | 2004-03-16 | Glaxosmithkline Biologicals S.A. | Emulsiones de aceite en agua que contienen saponinas. |
US5965714A (en) | 1997-10-02 | 1999-10-12 | Connaught Laboratories, Inc. | Method for the covalent attachment of polysaccharides to protein molecules |
CN1263854C (zh) | 1997-11-06 | 2006-07-12 | 启龙股份公司 | 奈瑟球菌抗原 |
CA2307846A1 (fr) | 1997-11-21 | 1999-06-03 | Genset S.A. | Sequence genomique et polypeptides de chlamydia pneumoniae, leurs fragments et leurs utilisations, en particulier pour le diagnostic, la prevention ou le traitement d'une infection |
GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
WO1999028475A2 (fr) | 1997-11-28 | 1999-06-10 | Genset | Sequence genomique et polypeptides de chlamydia trachomatis, leurs fragments et leurs utilisations, en particulier, pour le diagnostic, la prevention et le traitement de l'infection |
AU754256C (en) | 1997-12-23 | 2004-05-20 | Pfizer Ireland Pharmaceuticals | Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines |
WO1999036544A2 (fr) | 1998-01-14 | 1999-07-22 | Chiron S.P.A. | Antigenes du $i(neisseria meningitidis) |
US7018637B2 (en) * | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
GB9806456D0 (en) * | 1998-03-25 | 1998-05-27 | Smithkline Beecham Biolog | Vaccine composition |
WO1999052549A1 (fr) | 1998-04-09 | 1999-10-21 | Smithkline Beecham Biologicals S.A. | Compositions adjuvantes |
EP1645631B1 (fr) | 1998-05-01 | 2007-10-24 | Novartis Vaccines and Diagnostics, Inc. | Antigènes de Neisseria meningitidis et compositions |
PT1741443E (pt) † | 1998-05-29 | 2014-07-31 | Novartis Vaccines & Diagnostic | Combinação de vacinas para a meningite b/c |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
NZ509986A (en) | 1998-08-19 | 2003-10-31 | Baxter Healthcare S | Immunogenic beta-propionamido-linked polysaccharide and oligosaccharide protein conjugates as vaccines |
US6128656A (en) * | 1998-09-10 | 2000-10-03 | Cisco Technology, Inc. | System for updating selected part of configuration information stored in a memory of a network element depending on status of received state variable |
JP2004511201A (ja) | 1998-10-09 | 2004-04-15 | カイロン コーポレイション | ナイセリアゲノム配列およびそれらの使用方法 |
SI1126876T1 (sl) | 1998-10-16 | 2007-08-31 | Glaxosmithkline Biolog Sa | Adjuvantni sistemi in vakcine |
CA2350775A1 (fr) | 1998-11-12 | 2000-05-18 | The Regents Of The University Of California | Sequence genomique de chlamydia pneumoniae |
GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
US6146902A (en) | 1998-12-29 | 2000-11-14 | Aventis Pasteur, Inc. | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
HUP0200664A2 (en) * | 1999-03-19 | 2002-06-29 | Smithkline Beecham Biolog | Streptococcus vaccine |
FR2791895B1 (fr) | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
JP2002541808A (ja) | 1999-04-09 | 2002-12-10 | テクラブ, インコーポレイテッド | ポリサッカリド結合体ワクチンのための組換えトキシンaタンパク質キャリア |
PL203951B1 (pl) | 1999-04-19 | 2009-11-30 | Smithkline Beecham Biolog | Kompozycja adiuwantowa, kompozycja szczepionki oraz sposób jej wytwarzania, szczepionka oraz zastosowanie |
EP2270172B1 (fr) | 1999-05-19 | 2016-01-13 | GlaxoSmithKline Biologicals SA | Compositions à base de combinaisons de Neisseria |
GB9918319D0 (en) * | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
US6531131B1 (en) * | 1999-08-10 | 2003-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for Neisseria meningitidis |
PL355163A1 (en) | 1999-09-24 | 2004-04-05 | Smithkline Beecham Biologicals S.A. | Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
BR0014285A (pt) | 1999-09-24 | 2002-05-21 | Smithkline Beecham Biolog | Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico |
GB9925559D0 (en) | 1999-10-28 | 1999-12-29 | Smithkline Beecham Biolog | Novel method |
EP1233784B1 (fr) * | 1999-12-02 | 2008-07-09 | Novartis Vaccines and Diagnostics, Inc. | Compositions et procedes de stabilisation de molecules biologiques lors dune operation de lyophilisation |
MXPA02006962A (es) | 2000-01-17 | 2002-12-13 | Chiron Spa | Vacuna de vesicula de membrana exterior que comprende proteinas de membrana exterior de neisseria meningitidis serogrupo b. |
CN100334214C (zh) | 2000-02-28 | 2007-08-29 | 启龙股份公司 | 奈瑟球菌蛋白质的杂交表达 |
US6800455B2 (en) * | 2000-03-31 | 2004-10-05 | Scios Inc. | Secreted factors |
GB0108364D0 (en) * | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
EA011480B1 (ru) | 2000-06-29 | 2009-04-28 | Глаксосмитклайн Байолоджикалс С.А. | Поливалентная вакцинная композиция |
WO2002002606A2 (fr) | 2000-07-03 | 2002-01-10 | Chiron S.P.A. | Immunisation contre une infection par chlamydia pneumoniae |
GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
ES2278786T3 (es) * | 2000-09-28 | 2007-08-16 | Novartis Vaccines And Diagnostics, Inc. | Composiciones de microparticulas y procedimientos de fabricacion de las mismas. |
CA2881568C (fr) | 2000-10-27 | 2019-09-24 | Novartis Vaccines And Diagnostics, Inc. | Acides nucleiques et proteines derives des groupes de streptocoques a et b |
AP1897A (en) | 2001-01-23 | 2008-10-10 | Aventis Pasteur | Multivalent Meningococcal polysaccharide-Protein Conjugate Vaccine. |
ES2399386T3 (es) * | 2001-04-05 | 2013-04-01 | Novartis Vaccines And Diagnostics, Inc. | Aumento de la inmunidad de las mucosas tras sensibilización parenteral |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
JP4522699B2 (ja) | 2001-10-03 | 2010-08-11 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | アジュバント化されたMeningococcus組成物 |
PT1490409E (pt) | 2002-03-26 | 2009-04-03 | Novartis Vaccines & Diagnostic | Sacáridos modificados possuindo uma estabilidade melhorada em água |
EP1506007B1 (fr) | 2002-05-14 | 2011-06-22 | Novartis Vaccines and Diagnostics S.r.l. | Vaccins combines destines a etre administres aux muqueuses pour l'immunisation contre la meningite bacterienne |
GB0302218D0 (en) | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
GB0220198D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Modified saccharides,conjugates thereof and their manufacture |
SI2351579T1 (sl) | 2002-10-11 | 2017-05-31 | Glaxosmithkline Biologicals Sa | Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam |
US10272147B2 (en) * | 2003-01-30 | 2019-04-30 | Glaxosmithkline Biologicals S.A. | Injectable vaccines against multiple meningococcal serogroups |
GB0409745D0 (en) * | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
ES2383209T3 (es) * | 2006-03-22 | 2012-06-19 | Novartis Ag | Regímenes para la inmunización con conjugados meningococicos |
US10828361B2 (en) * | 2006-03-22 | 2020-11-10 | Glaxosmithkline Biologicals Sa | Regimens for immunisation with meningococcal conjugates |
GB0822633D0 (en) * | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
GB2495341B (en) * | 2011-11-11 | 2013-09-18 | Novartis Ag | Fermentation methods and their products |
-
2001
- 2001-06-20 GB GBGB0115176.0A patent/GB0115176D0/en not_active Ceased
-
2002
- 2002-06-20 ES ES09075005.0T patent/ES2603275T3/es not_active Expired - Lifetime
- 2002-06-20 AT AT10007477T patent/ATE556718T1/de active
- 2002-06-20 CN CNB028124448A patent/CN100482273C/zh not_active Expired - Lifetime
- 2002-06-20 ES ES09075010.0T patent/ES2670219T3/es not_active Expired - Lifetime
- 2002-06-20 ES ES02755452T patent/ES2261705T5/es not_active Expired - Lifetime
- 2002-06-20 DK DK06075175.7T patent/DK1741442T3/da active
- 2002-06-20 US US10/481,457 patent/US8753651B2/en active Active
- 2002-06-20 TR TR2018/08055T patent/TR201808055T4/tr unknown
- 2002-06-20 MX MXPA03011462A patent/MXPA03011462A/es active IP Right Grant
- 2002-06-20 AT AT06075175T patent/ATE474594T1/de active
- 2002-06-20 RU RU2004101284/13A patent/RU2381814C2/ru not_active Application Discontinuation
- 2002-06-20 CN CNA2009101281393A patent/CN101524533A/zh active Pending
- 2002-06-20 TR TR2018/08026T patent/TR201808026T4/tr unknown
- 2002-06-20 EP EP10179797.5A patent/EP2277536B1/fr not_active Expired - Lifetime
- 2002-06-20 CN CN200910128141.0A patent/CN101524535B/zh not_active Expired - Lifetime
- 2002-06-20 AU AU2002321716A patent/AU2002321716B2/en not_active Expired
- 2002-06-20 WO PCT/IB2002/003191 patent/WO2003007985A2/fr active IP Right Grant
- 2002-06-20 DE DE122010000042C patent/DE122010000042I1/de active Pending
- 2002-06-20 DK DK10179797.5T patent/DK2277536T3/en active
- 2002-06-20 AT AT02755452T patent/ATE322287T1/de active
- 2002-06-20 PT PT02755452T patent/PT1401489E/pt unknown
- 2002-06-20 BR BR122019009186A patent/BR122019009186B8/pt not_active IP Right Cessation
- 2002-06-20 DE DE122011000003C patent/DE122011000003I1/de active Pending
- 2002-06-20 ES ES10179797.5T patent/ES2662015T3/es not_active Expired - Lifetime
- 2002-06-20 ES ES10007477T patent/ES2387592T5/es not_active Expired - Lifetime
- 2002-06-20 ES ES09075009.2T patent/ES2670196T3/es not_active Expired - Lifetime
- 2002-06-20 PT PT10007477T patent/PT2263688E/pt unknown
- 2002-06-20 DK DK02755452.6T patent/DK1401489T4/da active
- 2002-06-20 BR BR0210590-0 patent/BRPI0210590B8/pt not_active IP Right Cessation
- 2002-06-20 NZ NZ529881A patent/NZ529881A/xx not_active IP Right Cessation
- 2002-06-20 DE DE122010000041C patent/DE122010000041I1/de active Pending
- 2002-06-20 JP JP2003513590A patent/JP5075317B2/ja not_active Expired - Lifetime
- 2002-06-20 EP EP09075005.0A patent/EP2184071B1/fr not_active Expired - Lifetime
- 2002-06-20 EP EP10179806.4A patent/EP2277537B1/fr not_active Expired - Lifetime
- 2002-06-20 DK DK09075005.0T patent/DK2184071T3/en active
- 2002-06-20 CA CA2730856A patent/CA2730856C/fr not_active Expired - Lifetime
- 2002-06-20 EP EP06075175A patent/EP1741442B1/fr not_active Expired - Lifetime
- 2002-06-20 PT PT90750050T patent/PT2184071T/pt unknown
- 2002-06-20 DK DK09075006.8T patent/DK2189165T3/en active
- 2002-06-20 CA CA2641585A patent/CA2641585C/fr not_active Expired - Lifetime
- 2002-06-20 CA CA2450203A patent/CA2450203C/fr not_active Expired - Lifetime
- 2002-06-20 CN CN200910128140.6A patent/CN101524534B/zh not_active Expired - Lifetime
- 2002-06-20 DE DE60210456T patent/DE60210456T3/de not_active Expired - Lifetime
- 2002-06-20 ES ES06075175T patent/ES2347458T3/es not_active Expired - Lifetime
- 2002-06-20 DE DE122010000040C patent/DE122010000040I1/de active Pending
- 2002-06-20 DK DK10007477.2T patent/DK2263688T4/da active
- 2002-06-20 EP EP10180707A patent/EP2277539A3/fr not_active Ceased
- 2002-06-20 ES ES10179806.4T patent/ES2539134T3/es not_active Expired - Lifetime
- 2002-06-20 EP EP09075010.0A patent/EP2229954B1/fr not_active Expired - Lifetime
- 2002-06-20 PT PT101798064T patent/PT2277537E/pt unknown
- 2002-06-20 DE DE60237123T patent/DE60237123D1/de not_active Expired - Lifetime
- 2002-06-20 NZ NZ544332A patent/NZ544332A/en not_active IP Right Cessation
- 2002-06-20 EP EP09075009.2A patent/EP2216044B1/fr not_active Expired - Lifetime
- 2002-06-20 PT PT101797975T patent/PT2277536T/pt unknown
- 2002-06-20 ES ES09075006.8T patent/ES2573259T3/es not_active Expired - Lifetime
- 2002-06-20 EP EP09075006.8A patent/EP2189165B1/fr not_active Expired - Lifetime
- 2002-06-20 EP EP02755452.6A patent/EP1401489B2/fr not_active Expired - Lifetime
- 2002-06-20 EP EP10007477.2A patent/EP2263688B2/fr not_active Expired - Lifetime
- 2002-06-20 PT PT06075175T patent/PT1741442E/pt unknown
-
2007
- 2007-07-24 AU AU2007203442A patent/AU2007203442B2/en not_active Expired
-
2009
- 2009-01-09 US US12/351,281 patent/US8889152B2/en not_active Expired - Lifetime
- 2009-01-14 US US12/353,409 patent/US8852606B2/en active Active
- 2009-01-20 US US12/321,418 patent/US9782466B2/en not_active Expired - Lifetime
- 2009-01-20 US US12/321,417 patent/US9452207B2/en not_active Expired - Lifetime
- 2009-01-20 US US12/321,434 patent/US9782467B2/en not_active Expired - Lifetime
- 2009-01-20 US US12/321,420 patent/US20090130147A1/en not_active Abandoned
- 2009-01-20 US US12/321,464 patent/US9358278B2/en not_active Expired - Lifetime
- 2009-02-26 JP JP2009044925A patent/JP5380111B2/ja not_active Expired - Lifetime
- 2009-02-26 JP JP2009044924A patent/JP5220658B2/ja not_active Expired - Lifetime
- 2009-03-11 RU RU2009108660/10A patent/RU2528066C2/ru active
-
2010
- 2010-09-13 BE BE2010C031C patent/BE2010C031I2/fr unknown
- 2010-09-13 FR FR10C0043C patent/FR10C0043I1/fr active Active
- 2010-09-13 FR FR10C0042C patent/FR10C0042I1/fr active Active
- 2010-09-13 FR FR10C0044C patent/FR10C0044I1/fr active Active
- 2010-09-13 BE BE2010C033C patent/BE2010C033I2/fr unknown
- 2010-09-13 BE BE2010C032C patent/BE2010C032I2/fr unknown
- 2010-09-13 NL NL300459C patent/NL300459I2/nl unknown
- 2010-09-13 NL NL300460C patent/NL300460I2/nl unknown
- 2010-09-13 NL NL300458C patent/NL300458I2/nl unknown
- 2010-09-14 LU LU91732C patent/LU91732I2/fr unknown
- 2010-09-14 LU LU91734C patent/LU91734I2/fr unknown
- 2010-09-14 LU LU91733C patent/LU91733I2/fr unknown
- 2010-10-11 CY CY20101100902T patent/CY1110820T1/el unknown
- 2010-11-19 AU AU2010246331A patent/AU2010246331B2/en not_active Expired
-
2011
- 2011-01-13 BE BE2011C001C patent/BE2011C001I2/fr unknown
- 2011-01-13 LU LU91778C patent/LU91778I2/fr unknown
- 2011-01-14 FR FR11C0001C patent/FR11C0001I2/fr active Active
- 2011-01-18 CY CY2011001C patent/CY2011001I2/el unknown
-
2012
- 2012-08-03 CY CY20121100693T patent/CY1113020T1/el unknown
- 2012-10-05 JP JP2012222942A patent/JP2013007057A/ja not_active Withdrawn
-
2016
- 2016-05-18 CY CY20161100432T patent/CY1117528T1/el unknown
- 2016-10-21 CY CY20161101065T patent/CY1118130T1/el unknown
- 2016-10-31 US US15/339,741 patent/US10716841B2/en not_active Expired - Lifetime
-
2018
- 2018-03-30 CY CY20181100356T patent/CY1120499T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR11C0001I1 (fr) | ||
AP2003002829A0 (en) | Multivalent meningococcal polysaccharide-protein conjugate vaccine. | |
AU4673099A (en) | Use of bioadhesives and adjuvants for the mucosal delivery of antigens | |
WO2003051392A3 (fr) | Vaccin | |
WO2002032450A3 (fr) | Vaccins | |
AU2002353417A1 (en) | Adjuvanted antigenic meningococcal compositions | |
WO2003051288A3 (fr) | Vaccin mycobacterien | |
WO2002010343A3 (fr) | Vaccin a virus vivants sensible a la temperature contre le mycoplasma hyopneumoniae | |
MXPA02012951A (es) | Dispositivo de transmision de potencia que tiene estrias convexas. | |
AU2002342949A1 (en) | Vaccine composition comprising at least two valences, one with enhanced adjuvant and not the other | |
MXPA01013392A (es) | Insertador universal. |